Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 13/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 12/20 | 0.34 |
| ▸ | DRD3 | P35462 | 12/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180595 | 0.74 | CYP17A1 (0.41) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL5574210 | 0.69 | FGFR1 (0.34) | ALDH1A1 | |
| SCHEMBL3380288 | 0.68 | CYP11B2 (0.58) | CHRNB2CHRNA4 | |
| SCHEMBL5570925 | 0.68 | CYP1A2 (0.38) | HTR2A | |
| SCHEMBL1180209 | 0.68 | CYP17A1 (0.41) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL5573336 | 0.67 | CYP17A1 (0.43) | CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL4724470 | 0.67 | CYP11B2 (0.52) | CHRM3 | |
| SCHEMBL5573406 | 0.66 | CYP17A1 (0.44) | CHRNB2CHRNA4SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5572854 | 0.66 | CYP19A1 (0.43) | — | |
| SCHEMBL5573376 | 0.66 | CYP17A1 (0.42) | CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680079-B2 | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-03-25 | — | — | US | claimed |
| US-8680079-B2 | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-03-25 | — | — | US | disclosed |
| US-20070225232-A1 | Tetrahydro-Imidazo [1,5-A] Pyridyin Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225232-A1 | Tetrahydro-Imidazo [1,5-A] Pyridyin Derivatives as Aldosterone Synthase Inhibitors | CYP21A2, CYP11B1, REN | CHRNB2 1959/4885CHRNA4 2112/4885DRD2 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.